PURPOSE: The following is a summary of discussion at a United States FDA (Food and Drug Administration) public workshop reviewing potential trial designs and end points to develop therapies to treat localized prostate cancer. MATERIALS AND METHODS: The workshop focused on the challenge that drug and device development to treat localized prostate cancer has been limited by the large trial sizes and lengthy timelines required to demonstrate an improvement in overall or metastasis-free survival and by the lack of agreed on alternative end points. Additionally, evolving treatment paradigms in the management of localized prostate cancer include the widespread use of active surveillance of patients with low and some intermediate risk prostate cancer, and the availability of advances in imaging and genomics. RESULTS: The workshop addressed issues related to trial design in this setting. Attendees discussed several potential novel end points such as a delay of morbidity due to radiation or prostatectomy and pathological end points such as Gleason Grade Group upgrade. CONCLUSIONS: The workshop provided an open forum for multiple stakeholder engagement to advance the development of effective treatment options for men with localized prostate cancer.
PURPOSE: The following is a summary of discussion at a United States FDA (Food and Drug Administration) public workshop reviewing potential trial designs and end points to develop therapies to treat localized prostate cancer. MATERIALS AND METHODS: The workshop focused on the challenge that drug and device development to treat localized prostate cancer has been limited by the large trial sizes and lengthy timelines required to demonstrate an improvement in overall or metastasis-free survival and by the lack of agreed on alternative end points. Additionally, evolving treatment paradigms in the management of localized prostate cancer include the widespread use of active surveillance of patients with low and some intermediate risk prostate cancer, and the availability of advances in imaging and genomics. RESULTS: The workshop addressed issues related to trial design in this setting. Attendees discussed several potential novel end points such as a delay of morbidity due to radiation or prostatectomy and pathological end points such as Gleason Grade Group upgrade. CONCLUSIONS: The workshop provided an open forum for multiple stakeholder engagement to advance the development of effective treatment options for men with localized prostate cancer.
Entities:
Keywords:
United States Food and Drug Administration; drug development; equipment design; prostatic neoplasms; research design
Authors: Lurdes Y T Inoue; Daniel W Lin; Lisa F Newcomb; Amy S Leonardson; Donna Ankerst; Roman Gulati; H Ballentine Carter; Bruce J Trock; Peter R Carroll; Matthew R Cooperberg; Janet E Cowan; Laurence H Klotz; Alexandre Mamedov; David F Penson; Ruth Etzioni Journal: Ann Intern Med Date: 2017-11-28 Impact factor: 25.391
Authors: Martin T King; Paul L Nguyen; Ninjin Boldbaatar; Clare M Tempany; Robert A Cormack; Clair J Beard; Mark D Hurwitz; W Warren Suh; Anthony V D'Amico; Peter F Orio Journal: Cancer Date: 2018-07-05 Impact factor: 6.860
Authors: Hashim U Ahmed; Viktor Berge; David Bottomley; William Cross; Rakesh Heer; Richard Kaplan; Tom Leslie; Chris Parker; Clare Relton; Richard Stephens; Matthew R Sydes; Lindsay Turnbull; Jan van der Meulen; Andrew Vickers; Timothy Wilt; Mark Emberton Journal: Nat Rev Clin Oncol Date: 2014-04-22 Impact factor: 66.675
Authors: Jonathan P Jarow; Ian M Thompson; Paul G Kluetz; John Baxley; Rajeshwari Sridhara; Peter Scardino; Peter Carroll; Peter Albertsen; H Balentine Carter; Otis Brawley; Oliver Sartor; Howard Sandler; James J Kiefert; Ronald A Morton Journal: Urology Date: 2014-03-22 Impact factor: 2.649
Authors: Sonia S Hur; Michael Tzeng; Eliza Cricco-Lizza; Spyridon P Basourakos; Miko Yu; Jessica Ancker; Erika Abramson; Christopher Saigal; Ashley Ross; Jim Hu Journal: BMJ Surg Interv Health Technol Date: 2021-06
Authors: Tristan Barrett; Simon Pacey; Kelly Leonard; Jerome Wulff; Ionut-Gabriel Funingana; Vincent Gnanapragasam Journal: Eur Urol Open Sci Date: 2022-02-10